Personalis Reports $20.6 Million Revenue in Q1 2025, Driven by Pharma Tests and Population Sequencing

Personalis, Inc. reported a total revenue of $20.6 million for the first quarter of 2025, marking a 6% increase from $19.5 million in the same period of 2024. The growth was primarily driven by a 39% rise in revenue from pharma tests and services, which totaled $13.6 million, and a significant 181% increase in population sequencing revenue, which reached $4.2 million. However, this growth was partially offset by a 69% decline in enterprise sales, primarily due to reduced activity from Natera, which accounted for 12% of total revenue in Q1 2025 compared to 41% in Q1 2024.

The company's net loss for the first quarter of 2025 was $15.8 million, or $0.18 per share, an increase from a net loss of $13.0 million, or $0.26 per share, in the prior year. Total costs and expenses remained relatively stable at $38.3 million, slightly down from $38.4 million in the previous year. The cost of revenue decreased by 5% to $13.4 million, while research and development expenses were consistent at $12.6 million. Selling, general, and administrative expenses rose to $12.3 million, reflecting increased marketing efforts related to the NeXT Personal Dx test.

In terms of operational metrics, Personalis delivered 2,184 molecular tests in the first quarter of 2025, a 52% increase compared to the previous quarter. The company also raised $17.8 million in net proceeds from the sale of common stock under its At-The-Market (ATM) program, which is expected to support ongoing operational and capital needs. As of March 31, 2025, Personalis had cash and cash equivalents of $71.0 million and short-term investments totaling $114.7 million.

Strategically, Personalis has been focusing on expanding its product offerings and partnerships. The company entered into a Commercialization and Reference Laboratory Agreement with Tempus in November 2023, which allows Tempus to market the NeXT Personal Dx test. This partnership is expected to enhance the company's market presence and drive revenue growth in the clinical diagnostics sector. Additionally, Personalis is actively pursuing collaborations with leading cancer centers and academic institutions to build clinical evidence for its products and secure reimbursement coverage from Medicare and other payors.

Looking ahead, Personalis anticipates continued growth in revenue driven by increased demand for its genomic testing services, particularly in the oncology sector. The company is also focused on expanding its operational capacity and enhancing its product offerings to meet the evolving needs of its customers. However, it acknowledges the potential risks associated with market conditions, customer concentration, and the need for ongoing investment in research and development to maintain its competitive edge.